- Conditions
- Uveitis, Uveitis, Posterior, Uveitis, Intermediate
- Interventions
- Sham Injector, FAI Insert
- Drug
- Lead sponsor
- EyePoint Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 1
- States / cities
- Waltham, Massachusetts
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 24
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Branch Retinal Vein Occlusion
- Interventions
- Brolucizumab 6 mg, Aflibercept 2 mg, Sham injection
- Drug · Other
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 450 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 26
- States / cities
- Phoenix, Arizona • Mountain View, California • Santa Barbara, California + 21 more
- Conditions
- Macular Degeneration
- Interventions
- Abicipar Pegol, Ranibizumab, Sham Procedure
- Drug · Other
- Lead sponsor
- Allergan
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 949 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 73
- States / cities
- Birmingham, Alabama • Gilbert, Arizona • Phoenix, Arizona + 65 more
- Conditions
- Diabetes Mellitus, Diabetic Macular Edema
- Interventions
- ASP8232, ranibizumab, Placebo, Sham intravitreal (IVT) injection
- Drug · Other
- Lead sponsor
- Astellas Pharma Europe B.V.
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 96 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 21
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Arcadia, California + 18 more
- Conditions
- Macular Edema Associated With Diabetes Mellitus
- Interventions
- Standard of Care, Macugen
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 317 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2011
- U.S. locations
- 28
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Los Angeles, California + 24 more
- Conditions
- Age-Related Macular Degeneration
- Interventions
- E10030, ranibizumab, E10030 sham intravitreal injection
- Drug
- Lead sponsor
- Ophthotech Corporation
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 619 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 50
- States / cities
- Phoenix, Arizona • Bakersfield, California • Beverly Hills, California + 44 more
- Conditions
- Retinitis Pigmentosa, Usher Syndrome Type 2, Deaf Blind, Retinal Disease, Eye Diseases, Eye Diseases, Hereditary, Eye Disorders Congenital, Vision Disorders
- Interventions
- QR-421a, Sham-procedure
- Drug · Other
- Lead sponsor
- Laboratoires Thea
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 2
- States / cities
- Dallas, Texas • Madison, Wisconsin
- Conditions
- Diabetic Macular Edema
- Interventions
- Luminate 1.0mg, Luminate 2.0mg, Luminate 3.0mg, Avastin, Luminate 0.5mg
- Drug
- Lead sponsor
- Allegro Ophthalmics, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 218 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 17
- States / cities
- Phoenix, Arizona • Beverly Hills, California • Mountain View, California + 14 more
- Conditions
- Nonproliferative Diabetic Retinopathy
- Interventions
- Intravitreal aflibercept injection [IAI], Sham
- Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 402 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 71
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Arcadia, California + 63 more
- Conditions
- Wet Macular Degeneration
- Interventions
- KSI-301, Aflibercept, Sham Procedure
- Drug · Other
- Lead sponsor
- Kodiak Sciences Inc
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 559 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 59
- States / cities
- Phoenix, Arizona • Springdale, Arkansas • Bakersfield, California + 53 more
- Conditions
- Diabetic Macular Edema
- Interventions
- intravitreal ranibizumab 0.3 mg, dexamethasone intravitreal implant, Sham injection
- Drug · Procedure
- Lead sponsor
- Jaeb Center for Health Research
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 129 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 56
- States / cities
- Beverly Hills, California • Huntington Beach, California • Loma Linda, California + 47 more
- Conditions
- Macular Degeneration, Choroidal Neovascularization
- Interventions
- Verteporfin photodynamic therapy, Pegaptanib, Triamcinolone acetonide
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 111 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2005
- U.S. locations
- 1
- States / cities
- Austin, Texas
- Conditions
- Diabetic Retinopathy
- Interventions
- Laser Photocoagulation, Bevacizumab
- Procedure · Drug
- Lead sponsor
- Jaeb Center for Health Research
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 121 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2008
- U.S. locations
- 34
- States / cities
- Loma Linda, California • Palm Springs, California • Santa Barbara, California + 28 more
- Conditions
- Diabetic Retinopathy
- Interventions
- BI 764524, Sham control of BI 764524
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 13
- States / cities
- Dothan, Alabama • Beverly Hills, California • Palo Alto, California + 10 more
- Conditions
- Non-proliferative Diabetic Retinopathy
- Interventions
- OTX-TKI, Sham
- Drug
- Lead sponsor
- Ocular Therapeutix, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 10
- States / cities
- Phoenix, Arizona • Bakersfield, California • Augusta, Georgia + 7 more
- Conditions
- Diabetic Macular Edema (DME)
- Interventions
- AKB-9778, ranibizumab, Placebo, Sham
- Drug
- Lead sponsor
- Aerpio Therapeutics
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 144 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 39
- States / cities
- Pheonix, Arizona • Tucson, Arizona • Arcadia, California + 35 more
- Conditions
- Geographic Atrophy, Macular Degeneration
- Interventions
- Avacincaptad Pegol, Sham
- Drug
- Lead sponsor
- IVERIC bio, Inc.
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 448 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 96
- States / cities
- Beverly Hills, California • Campbell, California • Fresno, California + 86 more
- Conditions
- Age-related Macular Degeneration (AMD)
- Interventions
- LMG324, Ranibizumab 0.5 mg, Sham
- Biological
- Lead sponsor
- Alcon Research
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 1
- States / cities
- Fort Worth, Texas
- Conditions
- Macular Degeneration
- Interventions
- Regorafenib, ophthalmic oily suspension (BAY73-4506), Sham IVT, Ranibizumab, Placebo
- Drug · Procedure
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 52 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 37
- States / cities
- Tucson, Arizona • Arcadia, California • Beverly Hills, California + 34 more
- Conditions
- Neovascular Age-related Macular Degeneration
- Interventions
- UBX1325 injection 50 μL, EYLEA® (aflibercept) Injection 2 mg (0.05mL)
- Drug
- Lead sponsor
- Unity Biotechnology, Inc.
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 51 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 14
- States / cities
- Beverly Hills, California • Huntington Beach, California • Longmont, Colorado + 11 more
- Conditions
- Diabetic Macular Edema
- Interventions
- IVT aflibercept, Sham SC, SC CLS-TA
- Drug
- Lead sponsor
- Clearside Biomedical, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 71 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 29
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Bakersfield, California + 25 more
- Conditions
- Non-Proliferative Diabetic Retinopathy
- Interventions
- Single intravitreal injection of axitinib hydrogel implant followed by a mock (sham) injection procedure at Week 24, Intravitreal injection of axitinib hydrogel implant followed by a second intravitreal injection of the axitinib implant at Week 24, Sham/mock procedure of intravitreal injection followed by a second sham/mock procedure at Week 24
- Drug · Other
- Lead sponsor
- Ocular Therapeutix, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 930 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- Hagerstown, Maryland
- Conditions
- Age-related Macular Degeneration
- Interventions
- AGN-150998, ranibizumab, Sham Injection
- Drug · Other
- Lead sponsor
- Allergan
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 271 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2014
- U.S. locations
- 1
- States / cities
- Phoenix, Arizona
- Conditions
- Geographic Atrophy
- Interventions
- JNJ-81201887, Prednisone, Placebo, Triamcinolone, Sham Procedure
- Drug · Other
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 60 Years and older
- Enrollment
- 305 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 79
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Fullerton, California + 66 more